Description
Cyclo(-RGDfK) is a potent and selective inhibitor of the αvβ3 integrin, with an IC50 of 0.94 nM[1]. Cyclo(-RGDfK) TFA potently targets tumor microvasculature and cancer cells through the specific binding to the αvβ3 integrin on the cell surface[2].–80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)–Cancer-programmed cell death–C27H41N9O7—ACS Appl Mater Interfaces. 2019 Jul 31;11(30):26648-26663. |Acta Biomater. 2021 Mar 9;S1742-7061(21)00152-5.|Adv Healthc Mater. 2021 May 29;e2100304.|Bioact Mater. 2021 Jan 7;6(7):2039-2057.|Biochem Biophys Res Commun. 2023 May 23.|Drug Deliv Transl Res. 2024 Mar 18.|Engineering. 8 October 2020.|Mater Today Nano. 2023 Nov 10, 100432.|Mol Ther Nucleic Acids. 2021 Jan 9;23:797-810.|Acs Biomater Sci Eng. 2023 Apr 24.-[1]Simecek J, et al. Benefits of NOPO as chelator in gallium-68 peptides, exemplified by preclinical characterization of (68)Ga-NOPO-c(RGDfK). Mol Pharm. 2014 May 5;11(5):1687-95.|[2]Lopez-Rodriguez V, et al. Preparation and preclinical evaluation of (66)Ga-DOTA-E(c(RGDfK))2 as a potential theranostic radiopharmaceutical. Nucl Med Biol. 2015 Feb;42(2):109-14.–161552-03-0–603.67–98.0–O=C([C@H](CCCCN)NC([C@@H](CC1=CC=CC=C1)NC([C@H](CC(O)=O)NC(CN2)=O)=O)=O)N[C@@H](CCCNC(N)=N)C2=O–Cancer–DMSO : 83.33 mg/mL (ultrasonic)|H2O : 50 mg/mL (ultrasonic)–Integrin–αvβ3–Cytoskeleton–Peptides
